Vivien Chan and Anna Mae Koo of Vivien Chan & Co discuss how technological developments in areas such as AI and e-commerce are reshaping intellectual property protection strategies and how companies ...

After decades of accusations over counterfeiting foreign brands, Chinese companies are now assuming dual roles: as not only IP violators, but also IP proprietors. BYD, DeepSeek, and Pop Mart are among ...

London, June 17, 2025: In a new expert interview, Stephen Yang, Managing Partner of IP March, shares practical insights into the changing intellectual property landscape in China with Lucy James, ...

China’s National Intellectual Property Administration (CNIPA) and Ministry of Industry and Information Technology (MITT) have unveiled a package of policy measures designed to strengthen intellectual ...

With the continuous facilitation of global trade, the transnational flow of infringing goods has intensified, posing a systematic threat to the intellectual property (IP) ecosystem and the economic ...

With the proliferation of e-commerce and the platform economy, Internet sales in counterfeits from China have exploded in recent years. China is estimated to produce 80% of the world’s counterfeits, ...

Bin Zhang and Yue Zheng of CCPIT round up the standard procedures and new measures involved in Customs protection for intellectual property in China With the first Regulations on Customs Protection of ...

RWS (RWS.L), a global AI solutions company, has been named Outstanding IP Service Team in China 2025 at the Enterprise IP Strategy Forum and Annual Conference of In-house IP Managers in Beijing.

An ambitious, ‘new generation’ IP law firm, Mizar IP has made significant inroads into China’s saturated intellectual property legal market since its founding in 2018. The boutique firm has shifted ...

Data released by the National Intellectual Property Administration (NIPA) showed that China's valid invention patents have reached 5.32 million, making it the first country in the world to surpass the ...

Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using ...